Marc BONNIN has more than 15 years of experience in the biological and immunological environment since 2005.
He first worked as an engineer in several Contract Research Organizations, followed by 6 years of experience in the field of Toll-like Receptor 3 acquired during his PhD in immuno-oncology and during his post-doctoral fellowship in virology.
Convinced by the key roles of TLR3 as a promise target in cancer and passionate by new challenges, he joined TOLLYS in 2017, and highly contributed to the discovery of the innovative dsRNAs TLR3 agonists family, with the identification of TL-532 as the leader anti-cancer molecule (Patent WO2019211492; 2018; Bonnin M., Thierry S.).
Head of the Discovery Unit in TOLLYS, he is in charge, among others, to improve the molecule designs for further systemic delivery. Moreover, he is in charge to evaluate new TLR3 therapeutic targets against both cancer and chronic virologic infections where urgent innovative drugs are needed.
He has got a French engineer degree (2004, Polytech’Clermont-Ferrand) and a US master degree in biotechnology (2004, Norman University, OK, USA) following by 4 years of experience in two CROs (2005-2009). He has got a PhD (2010-2013) in immuno-oncology aiming at targeting the innate immune receptor TLR3 against cancer (Centre de Recherche en Cancérologie de Lyon CRCL), and obtained a ROCHE post-doctoral fellowship in order to evaluate the anti-HBV effects induced by innate immune TLR3-7-9 activation in hepatocytes from 2014 to 2016 (INSERM U1052, Lyon, France).
He is the author of 10 scientific publications and one patent.
Cutting-Edge Cancer Immunotherapy
60F avenue Rockefeller
69008 Lyon, FRANCE